Biome Australia : Appendix 4D and Half Yearly Report

Biome Australia Limited

Appendix 4D

Half-year report

	1. Company details
	Name of entity:	Biome Australia Limited
	ABN:	51 627 364 014
only	For the half-year ended 31 December 2021
	Reporting period:
	Previous period:	For the half-year ended 31 December 2020
	2. Results for announcement to the market
					$
	Revenues from ordinary activities	up	98.2%	to	1,802,611
use
	Loss from ordinary activities after tax attributable to the owners of Biome
	Australia Limited	down	25.2%	to	(2,479,914)
	Lo for the half-year attributable to the owners of Biome Australia
	Limited	down	25.2%	to	(2,479,914)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

personalComments

The loss for the consolidated entity after providing for income tax amounted to $2,479,914 (31 December 2020: $3,314,622). Fi ancial Performance

During the half year period, the Company experienced strong sales growth with revenue increasing by 98.2% to $1,802,611 c mpared to the previous corresponding period (1H21 $909,561). The strong sales growth has been driven primarily by Biome's Activated Probiotics, live biotherapeutics (probiotics).

Retail pharmacy partner, Terry White Chemmart and pharmacy wholesaler Symbion, both reported that Biome's Activated P obiotics is the number one growth brand in the professional vitamin category within their networks for the 12 months to October 2021. The sales trajectory has also benefitted from the progressive easing of the COVID-19 lockdown restrictions throughout Australia and the consequential return of active field sales.

The loss for the consolidated entity after providing for income tax amounted to $2,479,914 (31 December 2020: $3,314,622). Sales and marketing costs increased by $142,152 to $1,879,668 as a result of increased expenditure on promoting the Company's products.

During the half year the Company strengthened its product portfolio through the launch of Biome Eczema Probiotic and ForBiome Her Probiotic, opening up new patient customer segments. Feedback from customers (health professionals) has been fav urable, reporting positive patient outcomes and improvements in both mild eczema and female genitourinary health

c ncerns following use of Biome Eczema Probiotic and Biome Her Probiotic, respectively.

Biome's largest distribution channel continues to be community pharmacy. Recent launches into the health food and practitioner channels with distributors, Oborne Health, Rener Health, Ariya and Vital.ly have supported growth in this new channel. Independent health practitioners now represent more than 20% of Biome's total sales.

Financial Position

During the financial year, the Company raised $8 million before capital raising costs through an initial public offering and had $7,743,968 in cash as at 31 December 2021.

The net assets of the Company increased by $7,005,585 from June 2021 to $8,585,713 as at 31 December 2021 which was a result of the Company's IPO and capital raising.

Biome Australia Limited

Appendix 4D

Half-year report

3.	Net tangible assets
onlyN t applicable.	Reporting		Previous
period		period
Cents		Cents
	Net tangible assets per ordinary security	4.29	0.52
4.	Control gained over entities
use
5.	Loss of control over entities
	Not applicable.
6.	Dividends
	Current period
	There were no dividends paid, recommended or declared during the current financial period.
personal
	Previous period
	There were no dividends paid, recommended or declared during the previous financial period.
7.	Dividend reinvestment plans
	N	t applicable.
8.	Details of associates and joint venture entities
	Not applicable.
9.	Foreign entities
	Details of origin of accounting standards used in compiling the report:
	Not applicable.
	10. Audit qualification or review
	Details of audit/review dispute or qualification (if any):
ForThe financial statements were subject to a review by the auditors and the review report is attached as part of the Interim
	Report.

11. Attachments

Details of attachments (if any):

The Interim Report of Biome Australia Limited for the half-year ended 31 December 2021 is attached.

Biome Australia Limited

Appendix 4D

Half-year report

12. Signed

personalForuse only	Date: 25 February 2022
Signed ___________________________
Mr Ilario Faenza
Chairman

onlyBiome Australia Limited

ABN 51 627 364 014

useInterim Report - 31 December 2021 personalFor

Biome Australia Limited Corporate directory

31 December 2021

Directors

onlyCompany secretary Registered office

Pri cipal place of business

Share register useAuditor

Stock exchange listing

Website personalFor

Blair William Brabin Vega Norfolk (Managing Director)

Ilario Thomas Faenza (Non-Executive Director)

Dominique Gayle Fisher (Independent Non-Executive Director)

George Lazarou

16 Dover Street

Cremorne Victoria 3121

16 Dover Street

Cremorne Victoria 3121

Automic Pty Ltd

JTP Assurance

Level 10, 446 Collins Street

Melbourne VIC 3000

Biome Australia Limited shares are listed on the Australian Securities Exchange (ASX code: BIO)

https://biomeaustralia.com/

1